Code over Control Groups

Are we witnessing the end of traditional clinical trials as we know them? The rise of real-world evidence and AI-powered simulations is disrupting the century-old model of controlled studies; offering faster, more efficient, and cost effective pathways to drug approval that bypass many of the limitations that have plagued pharmaceutical research for decades. As providers expand their biopharma services, companies are increasingly using massive datasets to conduct research that captures patient experiences in ways traditional trials never could, while digital device trials are eliminating geographic barriers and collecting continuous data streams that make conventional study designs look antiquated. This moonshot exploration of the future of traditional clinical trials will light the path toward a hybrid model that transforms how we validate new treatments. We're entering an era where code might matter more than control groups, and patient data streams could surpass traditional study designs.